|Bid||0.1800 x N/A|
|Ask||0.1900 x N/A|
|Day's Range||0.1850 - 0.1900|
|52 Week Range||0.1800 - 0.3950|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Rakovina Therapeutics Inc. (the "Company") (TSXV: RKV) today announced that the Company has been granted patents entitled "Tricyclic Inhibitors of Poly(ADP-Ribose) Polymerase" by the European and Canadian Patent Offices.
Rakovina Therapeutics Inc. (the "Company") (TSXV: RKV) is pleased to announce the appointment of Julie M. Cherrington, PhD to the Company's Board of Directors.
Vancouver, British Columbia--(Newsfile Corp. - April 5, 2021) - Rakovina Therapeutics Inc. is one of the latest new listings on the TSX Venture Exchange, trading under the symbol "RKV", following its qualifying transaction with Capital Pool Company Vincero Capital. The company's focus is the development of new cancer treatments and is researching and developing new precision medicines targeting critical DNA damage response mutations that are the hallmarks of many cancers.For more information, please view ...